Mathias Schmidt
Directeur/Membre du Conseil chez JCR PHARMACEUTICALS CO., LTD.
Postes actifs de Mathias Schmidt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Directeur/Membre du Conseil | 01/06/2020 | - |
| Corporate Officer/Principal | 01/06/2020 | - | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/10/2016 | - |
| Directeur Général | - | - | |
| JCR USA, Inc. | Directeur Général | - | - |
| President | - | - |
Historique de carrière de Mathias Schmidt
Formation de Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Allemagne | 3 |
| Japon | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
- Bourse
- Insiders
- Mathias Schmidt
- Expérience
